Keywords: AVEO Pharma, Tivozanin, Renal cell carcinoma, RCC, Bayer, Nexavar, Ph III, Regulatory filing planned
AVEO and Astellas’ tivozanib beats sorafenib in Ph III TIVO-1 trial
Article | 04 January 2012
US cancer drug developer AVEO Pharmaceuticals (Nasdaq: AVEO)) and partner Japanese drug major Astellas Pharma (TYO: 4503) say that tivozanib demonstrated ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- US Supreme Court says patent settlement can "sometimes" be illegal
- Negative US patent ruling for Novo Nordisk on Prandin
- Daiichi Sankyo files for Japanese approval of Prasugrel
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
